ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...
Seeking Alpha

Regenxbio's Vector Technology Will Change Gene Therapy

Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
PharmiWeb

Viral Vector Manufacturing Market Growth, Segments, Size, Market Analysis and Opportunities 2030

OverviewThe global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...
The Pharma Letter

ProteoNic 2G UNic technology licensed by Ginkgo Bioworks

Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been ...
GEN

Vector Production Would Benefit from Purpose-Built Processing Technology

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
Firehouse

Vector Solutions Acquires Envisage Technologies

TAMPA, FL and BLOOMINGTON, IN - (Sept. 8, 2021) - Vector Solutions, the leading provider of industry-focused software solutions for training, workforce management and risk communications, has acquired ...